Results 1 to 10 of about 1,139 (118)

Case Report: Central nervous system relapse treated with elranatamab after prior BCMA and GPRC5D directed therapies in relapsed/refractory multiple myeloma. [PDF]

Front Oncol
Central nervous system (CNS) involvement in multiple myeloma is a rare manifestation associated with aggressive disease biology and a particularly poor prognosis.
Pérez-Calle R, Domingo-González A, López-Lorenzo JL, Bastidas-Tamayo JF, Gutiérrez-San José B, Mata-Serna R, García-Corral B, Santiago-Álvarez JL, Vega-Achabal G, Llamas-Sillero P, Askari E.   +10 more
europepmc   +2 more sources

First-in-human evaluation of a no-alpha interleukin-2 mutein: safety and preliminary pharmacodynamic and clinical effect. [PDF]

Front Immunol
IntroductionInterleukin 2 (IL-2) is essential for immune system activation. To reduce toxicity and prevent the activation of regulatory T cells (T-regs), a novel IL-2 variant containing 4-point mutations that prevent its interaction with the alpha chain ...
Caballero Aguirrechu I, Mestre Fernández B, Soriano García JL, Lim Alonso N, Soto García A, Fleites Calvo V, Mariño de la Puente D, Vega Carvajal G, Ávila Pérez JC, Mendoza Hernández I, García López E, Tarinas Reyes A, García-Pérez G, Díaz Borges C, Ledón Naranjo N, Lozada Chang SL, García Vega Y, Alvárez Lobaina A, Alvárez Cardona M, Lorenzo-Luaces Alvárez P, Crombet Ramos T, Carmenate Portilla T, León Monzón K.   +22 more
europepmc   +2 more sources

Herederos: Ponte, García Vega y Casal

Anclajes, 2021
En este trabajo me propongo analizar un aspecto puntual en las relaciones literarias entre Antonio José Ponte y Lorenzo García Vega basándome en los ensayos que ambos le dedican a la obra de Julián del Casal. En la primera parte, repongo los principales
Ignacio Iriarte
doaj   +13 more sources

Evaluation of the epidemiological and economic impact of the ADLIFE intervention on medium- to long-term in patients with advanced chronic disease. [PDF]

Front Public Health
IntroductionPatients with advanced chronic disease (ACD) experience transitions in their clinical stability, leading to increased healthcare resource use and costs.
Larrañaga I, Mar J, Gorostiza A, García-Lorenzo B, Zubeltzu B, Vega R, Kaye R, Levy G, Vishnevetsky O, Lyngholm Christensen R, Dichmann Sorknæs A, Garton N, Swoboda A, Arndt F, McCann L, Maguire R, Miller M, Laleci Erturkmen GB, Yuksel M, Arvanitis TN, Tong C, Aznar-Baranda JI, Caballero J, González N, de la Torre J, Verdoy D, de Manuel Keenoy E, Fullaondo A, ADLIFE Consortium.   +28 more
europepmc   +2 more sources

Impact of patient safety on hospital prognosis: Association between adverse events and in-hospital mortalit. [PDF]

Clin Med (Lond)
Introduction: Adverse events (AEs) involve a safety problem and compromise the quality of care, but evidence on how they affect the prognosis of patients is limited.
Roncal-Redin M, San Jose-Saras D, Díaz-Agero Pérez C, Vicente-Guijarro J, Moreno-Nunez P, Pardo-Hernandez A, Aranaz-Andrés JM, ESHMAD director group and external advisers.   +7 more
europepmc   +2 more sources

Assessment of the ADLIFE intervention as a digital solution for patients with advanced chronic diseases: a quasi-experimental trial. [PDF]

NPJ Digit Med
This multicentre, non-randomized, quasi-experimental study evaluated the effectiveness of the ADLIFE digital toolbox—comprising clinical decision support, care-plan management, and patient empowerment—for patients aged >55 with chronic obstructive ...
García-Lorenzo B, Gorostiza A, González N, Larrañaga I, Moro Á, Ortega-Gil A, Zubelzu B, Vega R, de La Higuera L, Kaye R, Levy G, Vishnevetsky O, Sorknæs AD, Christensen RL, Juul NK, Randeva H, Robbins T, Yorkston M, Laleci Erturkmen GB, Yuksel M, Sarigul B, Arvanitis TN, Pournik O, Tong C, Aznar-Baranda JI, Caballero-García J, Vallejo-Setién G, Lilja M, Sherman MH, Swoboda A, Groene O, Bloemeke-Cammin J, Kalra D, Maguire R, McCann L, Miller M, López NFG, de Elguea LO, Lana MÁO, Alayo I, Aguirre U, Perea BL, Yeshayahu M, Halevy ED, Panchal S, Yılmaz G, de La Torre J, Verdoy D, de Manuel Keenoy E, Fullaondo A.   +49 more
europepmc   +2 more sources

Venous thromboembolism in patients with breast, ovarian, and uterine cancer. A comparative analysis from the Registro Informatizado Enfermedad TromboEmbólica registry. [PDF]

Res Pract Thromb Haemost
Background: The risk of recurrent venous thromboembolism (VTE) and bleeding during anticoagulation may vary by the cancer type. Objectives: We assessed outcomes during anticoagulation in women with breast, ovarian, or uterine cancer and VTE.
Sebastián OG, Trujillo-Santos J, Díaz-Pedroche MDC, Demelo-Rodríguez P, Otálora S, Brenner B, Pedrajas JM, Bura-Riviere A, Hernández-Blasco L, Monreal M, RIETE investigators.   +10 more
europepmc   +2 more sources

First year after surgery is the optimal period to define early prosthetic valve endocarditis: a cohort study. [PDF]

Open Heart
Background The definition of early prosthetic valve endocarditis (PVE) remains controversial. This study aims to refine the definition of early PVE by analysing data from the Spanish endocarditis registry (Spanish Collaboration on Endocarditis).Methods ...
Calderón-Parra J, Escrihuela F, Cuervo G, López-Azor JC, Muñoz P, Machado M, Marín M, Rodríguez-Esteban MÁ, Rodríguez-García R, Gutiérrez F, Miró Meda JM, Goenaga MÁ, Goikoetxea-Agirre J, de Alarcón A, Vidal-Bonnet L, Ramos-Martinez A, GAMES Investigators.   +16 more
europepmc   +2 more sources

Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE. [PDF]

Res Pract Thromb Haemost
Background: Low-molecular-weight heparins (LMWHs) are widely used in the treatment of cancer-associated venous thromboembolism (VTE), yet their long-term safety profiles remain insufficiently compared in clinical practice. Objectives: The primary outcome
Monreal M, Brenner B, Gómez-Cuervo C, Dally N, Alda-Lozano A, Pesce ML, Alfonso-Megido J, Hernández-Borge J, Mao RLE, Prandoni P, RIETE Investigators.   +10 more
europepmc   +2 more sources

Sos1 ablation alters focal adhesion dynamics and increases Mmp2/9-dependent gelatinase activity in primary mouse embryonic fibroblasts. [PDF]

Cell Commun Signal
Background Sos1 and Sos2 are guanine-nucleotide exchange factors for Ras and Rac small GTPases, which are involved in a wide range of cellular responses including proliferation and migration.
Liceras-Boillos P, Garcia-Navas R, Llorente-González C, Lorenzo-Martin LF, Luna-Ramírez L, Fuentes-Mateos R, Calzada N, Vega FM, Holt MR, Ridley AJ, Bustelo XR, Vicente-Manzanares M, Santos E, Baltanás FC.   +13 more
europepmc   +2 more sources